// App-Quantinova.ai

111 : Effects of the Novel Factor Xa Inhibitor, Apixaban, on Elevated Levels of Thrombotic Biomarkers in Genetically Obese, Diabetic Mice

Researchers

Presenter

  • Eileen Bird

Principal Investigators

  • Dietmar Seiffert

  • Robert Knabb

  • Bristol-Myers Squibb

Medical Centers

  • Res and Development, Pennington, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Venous thrombosis

  • Diabetes

  • Obesity

Biomarkers

  • Cluster of Differentiation 40

  • Interleukin 6

  • Soluble CD40-ligand

Drug/Treatment

  • Clopidogrel bisulfate

  • Interleukin

  • apixaban

  • Evithrom

  • Warfarin

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved